"The price of greatness is responsibility." Sir Winston Churchill


Search the IBPA



Top Menu

Menu Sidebar

IBPA Issues
About IBPA
IBPA Constitution
FAQ-s
IBPA Events
Individual Membership
Institutional Membership
IBPA Forums / Groups
Cooperation with IBPA
Links

Publications
IBPA Careers Newsletter
Past Issues
Industry Publications
Promote Yourself within the Industry
Submit Your Article

Career Center: Employers
Job Posting
Free Resume Database
Volunteers Database

Career Center: Job Seekers
Now Hiring
Submit Resume
Career Training
Nurses Careers in Biopharm
Scholarship Programs
Internship Programs
Resume Editing & Interview Coaching
Volunteer for the Industry
Download IBPA Career Info Brochure

Industry Directories and Listings
Pharmaceutical Companies
Contract Research Organizations
Professional Associations
Recruiters and Staffing Agencies
Clinical Research Centers
Consulting Companies
Education & Training Institutions
Jobs and Resume Searching Directories
Research and Development Companies
Industry Service Providers
List Your Company

Investor's Center
Offers
Calls

Contact IBPA
USAChapter
Canadian Chapter
European Chapter
Asian Chapter

Start Your Career in Biotech with IBPA Scholarship Programs
Untitled Document



Subscribe to our "Careers in the Biopharmaceutical Industry" newsletter:

Name*:

Email*:

City:

Country:

Phone:

To unsubscribe, click here

 

 

Genetic screen

From Wikipedia, the free encyclopedia.

 

A genetic screen (or simply screen) is a procedure or test to identify and select individuals which possess a phenotype of interest. A genetic screen for new genes is often referred to as forward genetics as opposed to reverse genetics that is the term used for identifying mutant alleles in genes that are already known. Mutant alleles that are not tagged for rapid cloning are mapped and cloned by positional cloning.

Contents

[hide]

[edit]

 

Creating a mutant population

Since unusual alleles and phenotypes are rare, geneticists expose the individuals that are to be screened to a mutagen, such as a chemical or radiation, which generates mutations in their chromosomes. The use of mutagens enables "saturation screens," one of the first of which was performed by Christiane Nüsslein-Volhard and Eric Wieschaus. A saturation screen is performed to uncover every genes that is involved in a particular phenotype in a given species. This is done by screening and mapping genes until no new genes are found. Mutagens such as random DNA insertions by transformation or active transposons can also be used to generate new mutants. These techniques have an advantage since a new allele is tagged with a known molecular (DNA) marker that can facilitate the rapid cloning of the gene without mapping.

[edit]

 

Types of screen

A basic screen involves looking for a phenotype of interest in the mutated population. One might screen for obvious phenotypes such a fruit flies with no wings or an Arabidopsis flower with no petals.

More subtle is a temperature sensitive screen that involves temperature shifts to enhance the mutant phenotype. A population grown at low temperature would have a normal phenotype, however, the mutation in the particular gene would make it unstable at a higher temperature. A screen for temperature sensitivity in fruit flies, for example, might involve raising the temperature in the cage until some flies faint, then opening a portal to let the others escape. Individuals selected in a screen are liable to carry an unusual version of a gene involved in the phenotype of interest. An advantage of alleles found in this type of screen is that the mutant phenotype is conditional and can be activated by simply raising the temperature. A null mutation in such a gene may be embryo lethal and such mutants would be missed in a basic screen.

An enhancer/supressor screen is the most sophisticated type of genetic screen. In this case a mutagenised population has an allele of a gene that leads to a weak mutant phenotype in the biological process of interest. For example, with regard to fruit fly wing development, a weak allele may have small abnormal wings whereas a strong/null allele would have no wings. In this sensitised background it is possible to discover new mutants that either enhance the phenotype (small wings to no wings) or suppress the phenotype (small wings to normal wings). Such a screen has two advantages. First, new genes identified in the screen are often involved in the same biological process as the weak allele in the genetic background, in this case wing formation. Second, due to genetic redundancy, the mutant genes discovered may not have a visible phenotype of their own. In a more basic screen these would not be discovered, however, in the sensitised genetic background a visible phenotype is clear.

[edit]

 

Mapping mutants

By the classical genetics approach, a researcher would then locate (map) the gene on its chromosome by crossbreeding with individuals that carry other unusual traits and collecting statistics on how frequently the two traits are inherited together. Classical geneticists would have used phenotypic traits to map the new mutant alleles. With the advent of genomic sequences for model systems such as Dropsophila, Arabidopsis and C. elegans many SNPs have now been identified that can be used as traits for mapping. SNPs are the prefered traits for mapping since they are very frequent, on the order of one difference per 1000 base pairs, between different varieties of organism.

[edit]

 

Positional cloning

For many genomes SNP's are not known and therefore positional cloning is required to identify polymorphisms that flank the mapped allele. This process requires that DNA fragments from the closest known genetic marker are progressively cloned getting closer to the mutant allele with each new clone. This process produces a contig map of the locus and is known as chromosome walking.

For each new DNA clone a polymorphism is identified and tested in the mapping population for it's recombination frequency compared to the mutant phenotype. When the DNA clone is at or close to the mutant allele the recombination frequency should be equal to zero. If the chromosome walk proceeds through the mutant allele the new polymorphisms will start to show increase in recombination frequency compared to the mutant phenotype. Depending on the size of the mapping population, and luck, the mutant allele can be narrowed down to a small region (<30 Kb). Sequence comparison between wild type and mutant DNA in that region is then required to locate the DNA mutation that causes the phenotypic difference.


External links




Learn More About the Biopharmaceutical Industry and Clinical Research:


Category:

Logo sidebar
  • Analytical Chemistry
  • Bioinformatics
  • Biology
  • Biochemistry
  • Biotechnology
  • Biotechnology Companies
  • Cell Imaging
  • Chemistry
  • Chemists
  • Crystallography
  • Ecology
  • Environmentalism
  • Genetic Engineering
  • Genetically Modified Organisms
  • Genetics
  • Health
  • Health Care
  • Health Sciences
  • Medical Specialities
  • Medicine
  • Molecular Genetics
  • Pharmaceutical Industry
  • Pharmacy
  • Pharmacology

  • Powered by Wikipedia, the free encyclopedia. Articles were developed by IBPA volunteers.

    Logo sidebar

    A

    B

    C

    D

    E

    F

    G

    I

    K

    L

    M

    N

    P

    Q

    R

    S

    T


    Logo sidebar


    IBPA Sponsors and Active Supporters

    http://www.payoneer.com/
    Access Clinical Trials

    Access Clinical Trials
    Access Clinical Trials


    Allied Research International
    Allied Research International

    Altaspera Global Services Inc.
    Altaspera Global Services

    Financial Planning and Personal Insurance
    For Canadian Pharmaceutical Industry Executives


    Biorole Scientific Solutions
    Biorole Scientific Solutions

    CEREPROTEC INC. Development of Novel Neuroprotective Drugs
    CEREPROTEC INC. Development of Novel Neuroprotective Drugs

    Recruitment Advertising Agencies
    Recruitment Advertising Agencies

    Cellular Technology Ltd.
    Cellular Technology Ltd.

    Clinical Trial Network
    Free Database of Clinical Investigators

    ClinQua Clinical Trials Inc.
    ClinQua Clinical Trials Inc.

    Coronis Clinical Research Organization
    Coronis Clinical Research Organization

    CPIC Latin America
    CPIC Latin America

    Espoir Bridge Recruiters
    Espoir Bridge Recruiters

    Genentech
    Genentech

    ILS SA
    Independent Research and Laboratory Solutions

    Inova Health Research
    Inova Health Research, Inc.

    Kriger Research Group International
    Kriger Research Group International

    LCCT
    LCCT

    Metrics Research
    Complete Research Solutions on a Single Platform

    Pharmalef Developments
    Pharmalef Developments

    PrimeHealth Clinical Research Organization
    PrimeHealth Clinical Research Organization

    Research & Development RA SA
    Research & Development RA SA

    Scios Inc.
    Scios Inc. - Manufacturer of Health Care Products

    Scios Inc.
    Southeast Regional Research Group LLC.

    UniMR
    UniMR Clinical Research

    YM BioSciences
    YM BioSciences

    Become IBPA Sponsor
    Post Your Logo Here

    ©2004 International Biopharmaceutical Association Inc., all rights reserved
    Privacy Policy - Terms of Use

    Google